AU Patent
AU2007243651B2 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Assigned to University of California San Diego UCSD · Expires 2012-08-30 · 14y expired
What this patent protects
A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
USPTO Abstract
A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
Drugs covered by this patent
- Erleada (apalutamide) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.